View ValuationSciDev 향후 성장Future 기준 점검 3/6SciDev (는) 각각 연간 106.7% 및 6.2% 수익과 수익이 증가할 것으로 예상됩니다.핵심 정보106.7%이익 성장률n/aEPS 성장률Chemicals 이익 성장42.6%매출 성장률6.2%향후 자기자본이익률4.01%애널리스트 커버리지Low마지막 업데이트20 Apr 2026최근 향후 성장 업데이트공지 • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.모든 업데이트 보기Recent updates공지 • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.공지 • Feb 23SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026공지 • Sep 17SciDev Limited, Annual General Meeting, Nov 20, 2025SciDev Limited, Annual General Meeting, Nov 20, 2025.공지 • Aug 25SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025공지 • Nov 21SciDev Limited Announces Resignation of Simone Watt as DirectorAs foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team.공지 • Sep 27SciDev Limited, Annual General Meeting, Nov 21, 2024SciDev Limited, Annual General Meeting, Nov 21, 2024.Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0.012 (vs AU$0.002 loss in FY 2023)Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 03First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023)First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.공지 • Sep 30SciDev Limited, Annual General Meeting, Nov 21, 2023SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.New Risk • Aug 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (€31.5m market cap, or US$34.0m).Reported Earnings • Feb 23First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022)First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Nov 29Independent & Non-Executive Director recently bought €52k worth of stockOn the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly €0.19 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €82k more in shares than they have sold in the last 12 months.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021)Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Dec 06Interim Chief Financial Officer Geoff Stephenson has left the companyOn the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months.Reported Earnings • Sep 03Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 168% per year, which means it is well ahead of earnings.Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Executive Departure • Jul 13Non-Executive Chairman Trevor Jones has left the companyOn the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (€248k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years.Is New 90 Day High Low • Feb 18New 90-day low: €0.42The company is down 18% from its price of €0.51 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.39 per share.Reported Earnings • Feb 11First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 10Revenue beats expectationsRevenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Nov 14New 90-day high: €0.53The company is up 32% from its price of €0.40 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period.이익 및 매출 성장 예측DB:INFA - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202811432516/30/20279313516/30/202687-202112/31/2025102-3-20N/A9/30/2025103-2-11N/A6/30/2025104-113N/A3/31/2025106146N/A12/31/2024109278N/A9/30/2024109267N/A6/30/2024109246N/A3/31/2024100125N/A12/31/202391003N/A9/30/202390004N/A6/30/202390015N/A3/31/202385004N/A12/31/2022811-12N/A9/30/2022680-20N/A6/30/202256-1-4-1N/A3/31/2022520-20N/A12/31/202148102N/A9/30/2021452-10N/A6/30/2021433-2-1N/A3/31/2021362-2-2N/A12/31/2020300-3-2N/A9/30/202024-1-2-1N/A6/30/202018-1-10N/A3/31/202013-1-2-2N/A12/31/20198-2-4-3N/A9/30/20195-2N/A-2N/A6/30/20193-2N/A-2N/A3/31/20193-1N/A-1N/A12/31/201821N/A-1N/A9/30/201821N/A-1N/A6/30/201821N/A-1N/A3/31/201820N/A-1N/A12/31/20172-1N/A-1N/A9/30/20172-1N/A0N/A6/30/20172-1N/A0N/A3/31/20172-1N/A0N/A12/31/20162-1N/A0N/A9/30/20161-1N/A0N/A6/30/201610N/A-1N/A3/31/20161-1N/A-1N/A12/31/20152-1N/A-1N/A9/30/20152-1N/A-1N/A6/30/20152-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: INFA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: INFA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: INFA 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: INFA 의 수익(연간 6.2%)이 German 시장(연간 6.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: INFA 의 수익(연간 6.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: INFA의 자본 수익률은 3년 후 4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 10:50종가2026/05/11 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SciDev Limited는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cameron BellCanaccord Genuitynull nullMacquarie ResearchStephen ScottTaylor Collison Limited
공지 • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.
공지 • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.
공지 • Feb 23SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026
공지 • Sep 17SciDev Limited, Annual General Meeting, Nov 20, 2025SciDev Limited, Annual General Meeting, Nov 20, 2025.
공지 • Aug 25SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025
공지 • Nov 21SciDev Limited Announces Resignation of Simone Watt as DirectorAs foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team.
공지 • Sep 27SciDev Limited, Annual General Meeting, Nov 21, 2024SciDev Limited, Annual General Meeting, Nov 21, 2024.
Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0.012 (vs AU$0.002 loss in FY 2023)Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 03First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023)First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
공지 • Sep 30SciDev Limited, Annual General Meeting, Nov 21, 2023SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (€31.5m market cap, or US$34.0m).
Reported Earnings • Feb 23First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022)First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Nov 29Independent & Non-Executive Director recently bought €52k worth of stockOn the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly €0.19 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €82k more in shares than they have sold in the last 12 months.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021)Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Dec 06Interim Chief Financial Officer Geoff Stephenson has left the companyOn the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months.
Reported Earnings • Sep 03Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 168% per year, which means it is well ahead of earnings.
Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Executive Departure • Jul 13Non-Executive Chairman Trevor Jones has left the companyOn the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (€248k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years.
Is New 90 Day High Low • Feb 18New 90-day low: €0.42The company is down 18% from its price of €0.51 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.39 per share.
Reported Earnings • Feb 11First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 10Revenue beats expectationsRevenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Nov 14New 90-day high: €0.53The company is up 32% from its price of €0.40 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period.